Who owns Artiva Biotherapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of ARTV from SEC Form 13F filings across 98 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 98 institutions disclosed 41.2M shares of Artiva Biotherapeutics, Inc. worth $287.3M — about 80.4% of shares outstanding; the largest disclosed holder is RA CAPITAL MANAGEMENT, L.P.. Source: SEC Form 13F filings, parsed by EvidInvest.
98
13F holders
$287.3M
value, 2026 filers
80.4%
of shares outstanding (41.2M sh)
32
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of ARTV's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 18.5M | $131.6M | 1.3% | 36.1% | +3.0% |
| 2 | VIKING GLOBAL INVESTORS LP | 2.6M | $18.5M | 0.1% | 5.1% | 0.0% |
| 3 | Blackstone Inc. | 2.4M | $17.1M | 0.0% | 4.7% | 0.0% |
| 4 | 5AM Venture Management, LLC | 2.4M | $16.8M | 5.6% | 4.6% | 0.0% |
| 5 | Venrock Adviser, LLC | 2.0M | $14.6M | 0.7% | 4% | 0.0% |
| 6 | FRANKLIN TEMPLETON INC | 2.0M | $8.6M | 0.0% | 4% | +2.2% |
| 7 | BlackRock, Inc. | 1.5M | $10.8M | 0.0% | 3% | +117.5% |
| 8 | Caligan Partners LP | 1.5M | $10.5M | 0.6% | 2.9% | -14.7% |
| 9 | SAMSARA BIOCAPITAL, LLC | 954,861 | $6.8M | 0.6% | 1.9% | 0.0% |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 942,367 | $6.7M | 0.0% | 1.8% | -4.0% |
| 11 | Propel Bio Management, LLC | 696,436 | $5.0M | 2.6% | 1.4% | 0.0% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 532,389 | $3.8M | 0.0% | 1% | +50.5% |
| 13 | Blue Owl Capital Holdings LP | 529,542 | $3.8M | 0.7% | 1% | -39.4% |
| 14 | STATE STREET CORP | 339,761 | $2.4M | 0.0% | 0.7% | +105.0% |
| 15 | Nantahala Capital Management, LLC | 300,000 | $2.1M | 0.1% | 0.6% | 0.0% |
| 16 | Revelation Capital Management, LLC | 299,311 | $2.1M | 26.6% | 0.6% | 0.0% |
| 17 | Alyeska Investment Group, L.P. | 273,615 | $1.9M | 0.0% | 0.5% | 0.0% |
| 18 | BOOTHBAY FUND MANAGEMENT, LLC | 268,188 | $1.9M | 0.0% | 0.5% | -14.7% |
| 19 | ACUTA CAPITAL PARTNERS, LLC | 260,416 | $1.9M | 1.4% | 0.5% | 0.0% |
| 20 | VANGUARD PORTFOLIO MANAGEMENT LLC | 259,504 | $1.8M | 0.0% | 0.5% | +734.1% |
| 21 | ACADIAN ASSET MANAGEMENT LLC | 216,631 | $1.5M | 0.0% | 0.4% | +844.3% |
| 22 | KVP Capital Advisors, LP | 200,000 | $1.4M | 1.1% | 0.4% | 0.0% |
| 23 | WELLINGTON MANAGEMENT GROUP LLP | 194,108 | $1.4M | 0.0% | 0.4% | 0.0% |
| 24 | NORTHERN TRUST CORP | 154,202 | $1.1M | 0.0% | 0.3% | +101.8% |
| 25 | GOLDMAN SACHS GROUP INC | 151,457 | $1.1M | 0.0% | 0.3% | +859.8% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.